Advanced Drug Delivery Systems Global Market Opportunities and Strategies to 2033

This report describes and explains the advanced drug delivery systems market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global advanced drug delivery systems market reached a value of nearly $259.24 billion in 2023, having grown at a compound annual growth rate (CAGR) of 6.2% since 2018. The market is expected to grow from $259.24 billion in 2023 to $373.4 billion in 2028 at a rate of 7.6%. The market is then expected to grow at a CAGR of 8.7% from 2028 and reach $566.44 billion in 2033.

Growth in the historic period resulted from the increased pharmaceutical research and development (R&D) expenditure, growing use of telemedicine services and rising healthcare expenditure. Factors that negatively affected growth in the historic period were product recalls.

Going forward, rising prevalence of chronic diseases, surging shift toward personalized medicine, increasing demand for early diagnosis of health problems and increasing growth in elderly population will drive the growth. Factor that could hinder the growth of the advanced drug delivery systems market in the future include risk of needlestick injuries.

The advanced drug delivery systems market is segmented by type into oral drug delivery system, injection-based drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery system and other types. The oral drug delivery system market was the largest segment of the advanced drug delivery systems market segmented by type, accounting for 39.9% or $103.46 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by type, at a CAGR of 9% during 2023-2028.

The advanced drug delivery systems market is segmented by application into oncology, anti-infective, central nervous system, respiratory diseases, cardiovascular diseases, musculoskeletal disorders, metabolic disorders and other applications. The other applications market was the largest segment of the advanced drug delivery systems market segmented by application, accounting for 19.2% or $49.86 billion of the total in 2023. Going forward, the oncology segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by application, at a CAGR of 9.9% during 2023-2028.

The advanced drug delivery systems market is segmented by end user into hospitals, specialized clinics and other end users. The hospitals market was the largest segment of the advanced drug delivery systems market segmented by end user, accounting for 51.9% or $134.65 billion of the total in 2023. Going forward, the other end users segment is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by end user, at a CAGR of 7.9% during 2023-2028.

The advanced drug delivery systems market is segmented by carrier type into liposomes, nanoparticles, microspheres, monoclonal antibodies and other carrier types. The nanoparticles market was the largest segment of the advanced drug delivery systems market segmented by carrier type, accounting for 28% or $72.58 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by carrier type, at a CAGR of 8.7% during 2023-2028.

The advanced drug delivery systems market is segmented by technology into prodrug, implants and intrauterine devices, targeted drug delivery, polymeric drug delivery and other technologies. The targeted drug delivery market was the largest segment of the advanced drug delivery systems market segmented by technology, accounting for 31.4% or $81.48 billion of the total in 2023. Going forward, it is expected to be the fastest growing segment in the advanced drug delivery systems market segmented by technology, at a CAGR of 8.7% during 2023-2028.

North America was the largest region in the advanced drug delivery systems market, accounting for 40% or $103.62 billion of the total in 2023. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the advanced drug delivery systems market will be Asia Pacific and Western Europe where growth will be at CAGRs of 8% and 7.8% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 7.6% and 6.5% respectively.

The global advanced drug delivery systems market is highly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up to 2.91% of the total market in 2022. The market concentration can be attributed to the presence of large number of players in different geographies. Prominent players are acquiring the products and entering into partnerships with the other companies to consolidate their market positions across the globe, while others are distributing products. Johnson & Johnson, Inc was the largest competitor with a 0.50% share of the market, followed by Baxter with 0.48%, Becton, Dickinson and Company with 0.46%, Medtronic Plc with 0.31%, Pacira BioSciences, Inc. with 0.26%, Abbvie, Inc. with 0.24%, Gilead Sciences, Inc. with 0.20%, Merck KGaA with 0.17%, Danaher Corporation with 0.14% and Bausch Health Companies Inc with 0.14%.

The top opportunities in the advanced drug delivery systems market segmented by type will arise in the oral drug delivery system segment, which will gain $56.07 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by application will arise in the oncology segment, which will gain $28.36 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by end user will arise in the hospitals segment, which will gain $58.53 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by carrier type will arise in the nanoparticles segment, which will gain $37.65 billion of global annual sales by 2028. The top opportunities in the advanced drug delivery systems market segmented by technology will arise in the targeted drug delivery segment, which will gain $42.22 billion of global annual sales by 2028. The advanced drug delivery systems market size will gain the most in the USA at $37.87 billion.

Market-trend-based strategies for the advanced drug delivery systems market include introducing preclinical drug development with advanced drug delivery technology, increasing focus dissolving microneedle drug delivery methods, innovative on-body delivery systems for subcutaneous therapies, pioneering advanced drug delivery with thin film formulation and strategic partnerships and collaborations among market players to drive innovation and expansion in the market.

Player-adopted strategies in the advanced drug delivery systems market include expanding operations by new drug developments/approvals, expanding operations through acquisitions, expanding operations through innovations and expanding operations through strategic acquisitions.

To take advantage of the opportunities, the analyst recommends the advanced drug delivery systems companies to focus on advancing preclinical drug development with innovative technology, focus on dissolving microneedle drug delivery methods, focus on on-body delivery systems for subcutaneous therapies, focus on technological advancements in drug delivery, focus on oral and inhalation drug delivery systems, focus on targeted drug delivery and polymeric drug delivery, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for brain-targeted drug delivery, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on tailored solutions for end-users and focus on hospitals segment.